Abstract
Background: UDP-glucuronosyltransferase 2B15 (UGT2B15) catalyzes the inactivation of dihydrotestosterone (DHT) by forming the DHT-glucuronide and is expressed in normal and hyperplastic prostate tissue. Alterations in the activity of this enzyme could be a major contributing factor to the bioavailability of androgens in target tissue such as the prostate.
Methods: A polymorphism (D85 to Y85) has been identified in the UGT2B15 gene1 that results in a 50% reduction in enzyme activity. Previously, detection of the polymorphic nucleotide has required direct sequencing. We have developed and validated an allele-specific polymerase chain reaction (PCR) assay to identify the polymorphic base pair in the UGT2B15 gene. This assay was used to examine the distribution of the UGT2B15 polymorphism in a small case-control group (64 cases and 64 controls) from a prostate cancer study.
Results: The results of this analysis show that prostate cancer patients were significantly more likely to be homozygous for the lower activity D85 UGT2B15 allele than control individuals (41% versus 19%, respectively, odds ratio 5 3.0 (95% confidence intervals 1.3– 6.5)).
Conclusions: These results suggest that individuals who are homozygous for the lower activity allele may be at increased risk for developing prostate cancer.
References
Levesque E, Beaulieu M, Green MD, Tephly TR, Belanger A, Hum DW. Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene.Pharmacogenetics 1997;7:317–325.
Burchell B, Nebert DW, Nelson DR, et al. The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biol 1991;10:487–494.
Mackenzie PI, Owens IS, Burchell B, et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997;7:255–269.
Strassburg CP, Nguyen N, Manns MP, Tukey RH. Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Mol Pharmacol 1998;54:647–654.
Iyanagi T. Molecular basis of multiple UDP-glucuronosyltransferase isoenzyme deficiencies in the hyperbilirubinemic rat (Gunn rat). J Biol Chem 1991;266:24048–24052.
Monaghan G, Clarke DJ, Povey S, See CG, Boxer M, Burchell B. Isolation of a human YAC contig encompassing a cluster of UGT2 genes and its regional localization to chromosome 4q13. Genomics 1994;23:496–499.
Ritter JK, Chen F, Sheen YY, Tran HM, Kimura S, Yeatman MT, Owens IS. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 1992;267:3257–3261.
Cappiello M, Giuliani L, Pacifici GM. Distribution of UDP-glucuronosyltransferase and its endogenous substrate uridine 5’- diphosphoglucuronic acid in human tissues. Eur J Clin Pharmacol 1991;41:345–350.
Ilett KF, Tee LB, Reeves PT, Minchin RF. Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol Ther 1990;46:67–93.
Mulder GJ. Glucuronidation and its role in regulation of biological activity of drugs. Annu Rev Pharmacol Toxicol 1992;32:25–49.
Green MD, Oturu EM, Tephly TR. Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. Drug Metab Dispos 1994; 22:799–805.
Belanger G, Beaulieu M, Marcotte B, Levesque E, Guillemette C, Hum DW, and Belanger A. Expression of transcripts encoding steroid UDP-glucuronosyltransferases in human prostate hyperplastic tissue and the LNCaP cell line. Mol Cell Endocrinol 1995;113:165–173.
Whittemore AS, Kolonel LN, Wu AH, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada [see comments]. J Natl Cancer Inst 1995;87:652–661.
Ross RK, Coetzee GA, Reichardt J, Skinner E, Henderson E. Does the racial-ethnic variation in prostate cancer risk have a hormonal basis? Cancer Supplement 1995; 75:1778–1782.
Carter BS, Steinberg GD, Beaty TH, Childs B, Walsh PC. Familial risk factors for prostate cancer. Cancer Surveys 1991;11:5–13.
Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 1992;89:3367–3371.
Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993;150:797–802.
Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of Prostate cancer. Prostate 1990;17:337–347.
Geller J, Albert J, de laVega D, Loza D, Stoeltzing W. Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency. Cancer Res 1978;38:4349–4352.
Cussenot O, Valeri A, Berthon P, Fournier G, Mangin P. Hereditary prostate cancer and other genetic predispositions to prostate cancer. Urol Int 1998;60(Suppl 2):30–34; discussion 35.
Klus GT, Nakamura J, Li JS, et al. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Cancer Research 1996;56:4956–4964.
Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999;20:1727–1731.
Makridakis N, Ross RK, Pike MC, et al. A prevalent missense substitution that modulates activity of prostatic steroid 5alphareductase. Cancer Res 1997;57:1020–1022.
Nowell SA, Leakey JE, Warren JF, Lang NP, Frame LT. Identi-fication of enzymes responsible for the metabolism of heme in human platelets. J Biol Chem 1998;273:33342–346.
Labrie F, Dupont A, Simard J, Luu-The V, Belanger A. Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur Urol 1993;24:94–105.
Labrie F, Belanger A, Simard J, Luu-The V, Labrie C. “Intracrinology”. Autonomy and freedom of peripheral tissues [in French]. Annales d Endocrinologie 1995;56:23–29.
Lorence MC, Corbin CJ, Kamimura N, Mahendroo MS, Mason JI. Structural analysis of the gene encoding human 3 beta-hydroxysteroid dehydrogenase/delta 5–4-isomerase. Mol Endocrinol 1990;4:1850–1855.
Andersson S, Bishop RW, Russell DW. Expression cloning and regulation of steroid 5 alpha-reductase, an enzyme essential for male sexual differentiation. J Biol Chem 1989;264:16249–16255.
Labrie F, Simard J, Luu-The V, et al. Structure and tissue-specific expression of 3 beta-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues. J Steroid Biochem Mol Biol 1992;41:421–435.
Labrie F, Sugimoto Y, Luu-The V, et al. Structure of human type II 5 alpha-reductase gene. Endocrinology 1992;131:1571–1573.
Sun XY, Plouzek CA, Henry JP, Wang TT, Phang JM. Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells. Cancer Res 1998;58:2379–2384.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
MacLeod, S.L., Nowell, S., Plaxco, J. et al. An Allele-Specific Polymerase Chain Reaction Method for the Determination of the D85Y Polymorphism in the Human UDPGlucuronosyltransferase 2B15 Gene in a Case-Control Study of Prostate Cancer. Ann Surg Oncol 7, 777–782 (2000). https://doi.org/10.1007/s10434-000-0777-3
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-000-0777-3